Evidence map›Paper›PMID 40354754›Full record

ArticleClinics (Sao Paulo, Brazil)2025

Methotrexate carried in lipid core nanoparticles reduces microglial activation and induces neuroprotection after cortical stroke induced in rats.

Edmundo L R Pereira, Raul C Maranhão, Michelle N C Dias, Ijair R Dos Santos, Carolina Ramos Dos Santos, Moisés Hamoy, Danielle Cristine A Feio, Priscila O Carvalho, Jaqueline M Bazioli, Aleksandra T Morikawa and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Edmundo L R PereiraLaboratory of Experimental Neuroprotection and Neuroregeneration, Institute of Collective Health, Universidade Federal do Oeste do Pará, Santarém, PA, Brazil; Neurology Unity, Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, Belém, PA, Brazil.
Raul C MaranhãoNeurology Unity, Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, Belém, PA, Brazil. Electronic address: ramarans@usp.br.
Michelle N C DiasLaboratório de Metabolismo e Lípides, Instituto do Coração (InCor-HCMUSP), Department of Cardiopneumology of the Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Ijair R Dos SantosLaboratório de Metabolismo e Lípides, Instituto do Coração (InCor-HCMUSP), Department of Cardiopneumology of the Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Carolina Ramos Dos SantosLaboratory of Experimental Neuroprotection and Neuroregeneration, Institute of Collective Health, Universidade Federal do Oeste do Pará, Santarém, PA, Brazil.
Moisés HamoyLaboratory of Toxicology and Natural Products, Institute of Biological Sciences, Universidade Federal do Pará, Belém, PA, Brazil.
Danielle Cristine A FeioLaboratory of Molecular Biology, Universidade Estadual do Pará, Belém, PA, Brazil.
Priscila O CarvalhoNeurology Unity, Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, Belém, PA, Brazil.
Jaqueline M BazioliNeurology Unity, Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, Belém, PA, Brazil.
Aleksandra T MorikawaNeurology Unity, Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, Belém, PA, Brazil.
Walace Gomes-LealLaboratory of Experimental Neuroprotection and Neuroregeneration, Institute of Collective Health, Universidade Federal do Oeste do Pará, Santarém, PA, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background This study aimed to investigate the effects of LDE-MTX on acute cerebral infarction. The study focuses on how LDE-MTX can influence the outcomes of ischemic stroke in a rat model, specifically examining its neuroprotective properties. Methods Radioactively labeled LDE uptake by brain tissue was determined after IV injection in rats with Endothelin-1 (ET-1)-induced cortical ischemic stroke (n = 11) and controls (n = 18). Two groups of 5 animals were treated with LDE-MTX (1 mg/kg, IV) or LDE-alone 4 h post-stroke induction. After 7days, tissues were analyzed by immunohistochemistry for neuronal bodies, astrocytes, and microglia. Results LDE uptake was fivefold higher in ischemic rats than in controls (p = 0.0003). LDE-MTX significantly inhibited microglial activation, resulting in a tenfold decrease in activated macrophages, and increased neuronal survival by 319 % in the periinfarct area. LDE-MTX had no effect on astrocytosis or primary infarct size. Conclusions LDE-MTX demonstrated neuroprotective effects and shows potential as a novel strategy to limit ischemic stroke damage. The results suggest that LDE-MTX could be a promising treatment option for reducing ischemic damage in stroke patients, particularly through its effect on microglial activation and neuronal survival.

Indexed as

MethotrexateMicrogliaNanoparticlesNeuroprotective AgentsStrokeAnimalsDisease Models, AnimalEndothelin-1ImmunohistochemistryMaleRatsRats, WistarEndothelin-1MethotrexateNeuroprotective AgentsDrug deliveryMethotrexate (Methotrexate)NeuroinflammationNeuroprotectionSolid lipid nanoparticles

Identifiers

PMID40354754
PMCPMC12139685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.